INVION APPOINTS MR THIAN CHEW AS DIRECTOR AND CHAIRMAN
Brisbane, Australia and Delaware, United States, 1 December 2017: Invion Limited (ASX: IVX) is pleased to announce the appointment of Mr Thian Chew as Non-Executive Director and Chairman of the Board of Directors.
Invion Managing Director and Chief Executive Officer Dr Greg Collier said: “We are delighted to welcome Thian to the Board. Following yesterday’s Annual General Meeting which saw Invion shareholders approving all resolutions relating to the licence to commercialise Photosoft™ for the treatment of cancers, we are very positive about the Company’s future and look forward to working together to progress clinical and commercial development plans.”
Mr Chew has over 25 years’ experience in investing, finance and transforming business operations. He is Managing Partner at Polar Ventures, a private investment and consulting firm that provides capital, strategic and operating solutions, focusing on small to mid-sized enterprises in Asia.
Mr Chew was previously an Executive Director at Goldman Sachs (Hong Kong and New York) responsible for the firm’s proprietary investments including growth capital, private equity and special situations in both private and public companies.
Prior to this, he was a Consultant Project Manager to Morgan Stanley, New York. Mr Chew also held a number of positions in KPMG across Asia Pacific including Director at KPMG Consulting (Singapore and Sydney) where he led several large scale operational restructuring, post-merger integration, transformation, and business performance improvement programs. As a Senior Manager at KPMG (Taipei and Melbourne), he led several business process re-engineering initiatives, and also performed financial and information technology audit, risk and assurance engagements across multiple industries.
Mr Chew holds an MBA from the Wharton School (Palmer Scholar), MA from the Lauder Institute, University of Pennsylvania, and a Bachelor of Information Systems from Monash University. Mr Chew is an Adjunct Professor at HKUST’s MBA program and previously qualified as a chartered accountant.
Dr Collier returns to MD and CEO role
Dr Greg Collier, who has acted as Interim Executive Chair since February 2016, returns to his role as Managing Director and CEO, effective immediately. The material terms of Dr Collier’s CEO contract have not changed other than, as proposed by Dr Collier and agreed by the Board, effective 1 December 2017, Dr Collier will be engaged at a 2/3 rate, with this being regularly reviewed.
Photosoft™ is a new generation photosensitiser derived from chlorophyll which is hypothesised to identify and selectively accumulate within solid cancerous tumour tissues. Photosoft™ is activated at multiple light sensitivity ranges across a broad spectrum, and therefore has potential to be targeted to both surface and deep seated tumours. ASX / MEDIA ANNOUNCEMENT Invion Limited ABN 76 094 730 417 GPO Box 1557, Brisbane, QLD, 4001. P +61 7 3295 0500 F +61 7 3295 0599 www.inviongroup.com
Invion has an agreement with The Cho Group to conduct clinical development of Photosoft™ globally, leveraging the Company’s expertise. The Cho Group will provide non-dilutive funding to Invion for R&D and clinical trials as part of a global development strategy for the asset. Invion has also been granted exclusivity in Australia and New Zealand to commercialise and distribute Photosoft™ for the treatment of cancers.